Fludarabine, cyclophosphamide, and ATG had superior outcomes versus historical outcomes of non-ATG conditioning. Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day. Danicopan as an add-on to C5 inhibitor therapy in patients with PNH with EVH showed sustained treatment benefits. Study finds a possible negative association between hemoglobin levels and certain von Willebrand factor assays. Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs. This would be the fourth authorized indication for luspatercept in the European Union. Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel. Exa-cel eliminated RBC transfusions in patients with transfusion-dependent β-thalassemia. HSCT with a matched unrelated or haploidentical donor was a promising alternative in patients with severe aplastic anemia. Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia. The US FDA extended the Priority Review period for the BLA for marnetegragene autotemcel in leukocyte adhesion deficiency-I. The European Commission has approved the Conditional Marketing Authorization for exagamglogene autotemcel. Low hemoglobin and anemia were found to be modifiable risk factors associated with low cognitive function in older patients. Desmopressin with FVIII during operations was reportedly feasible and safe in patients with nonsevere hemophilia A. C1-inhibitor administration during transfusions did not significantly suppress hemolysis in autoimmune hemolytic anemia. Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease. Patients with RA had a 57% increased risk of VTE; a 58% increased risk of DVT; and a 57% increased risk of PE. Thrombectomy treatment of iliofemoral DVT reduced the incidence of post-thrombotic syndrome compared with anticoagulants. Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading. The majority of newly diagnosed patients with PNH did not receive a PNH-specific therapy at diagnosis.